Head-to-head · WeighScore
This Gen Wellness vs Zealthy
The verdict
This Gen Wellness takes it — 56.9/100 to 46.7/100.
This Gen Wellness grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. This Gen Wellness is a New York-only telehealth practice operated by ThisGen, LLC, offering medically supervised weight loss alongside hormone therapy and ED care.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | This Gen Wellness | Zealthy |
|---|---|---|
| WeighScore | 56.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #405 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 1 state | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #405 · C
Strengths
- Requires a synchronous live audio-video visit with a New York-licensed clinician — prescriptions are never issued from the intake form alone
- Assessment and clinician review are free; you only pay if treatment is prescribed and you choose to proceed
- Names its legal entity (ThisGen, LLC) and specifies New York governing law in its terms
- No long-term contracts — plans can be paused or stopped
- The same clinician follows your care, with ongoing secure messaging between visits
Where it loses points
- Publishes no prices at all — 'We don't list flat prices on the website'; cost is disclosed only after a clinician reviews your assessment
- Serves New York only — 'we currently operate exclusively for patients located in New York'
- Dispensing pharmacies are not named, only described as 'licensed U.S. pharmacies'
- Does not state whether its semaglutide and tirzepatide are compounded or brand-name
- Does not bill insurance; verifying any reimbursement is the patient's responsibility
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.